Pure Global
NCT06105112

Periodontal Regeneration With Hyaluronic Acid or Enamel Matrix Derivatives

Minimally Invasive Periodontal Regeneration With a Combination Approach Using Either Hyaluronic Acid or Enamel Matrix Derivatives: a 24-month Multicenter Randomized Controlled Clinical Trial
University of Turin, Italy·ClinicalTrials.gov·device·Device trialRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Periodontitis
Drug/Device/Intervention
Hyaluronic acid
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
University of Turin, Italy
Location
Turin, Italy
Timeline & enrollment
Phase
N/A
Start date
Oct 01, 2023
End date
Oct 01, 2026
Enrollment
60 participants
Primary outcome

Clinical attachment level change

Summary

To date, the quest for ideal biological inductors for periodontal regeneration is still
 ongoing, especially when facing non-containing defect anatomies. The primary aim of this
 study is to evaluate the clinical and radiographic performance of a bone graft combined with
 either enamel matrix derivatives or hyaluronic acid for periodontal regeneration of
 non-containing intrabony defects in terms of clinical attachment gain (primary outcome) and
 other secondary outcomes (probing pocket depth reduction, radiographic bone fill). Moreover,
 this study aims to compare early wound healing and patient-reported outcome measures.

ICD-10 classifications
Chronic periodontitisPeriodontosisAcute periodontitisChronic apical periodontitisPeriodontal disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06105112
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06105112 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Turin, Italy and is currently Recruiting. The study focuses on Periodontitis. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.